ALT: altimmune.com Price to Earnings Adjusted for Growth Rate

The historical PEG ratio reflects the impact of partnership expectations for the final tests of the obesity drug. Altimmune, Inc. (ALT) develops advanced peptide therapies to combat metabolic disorders, leveraging US laboratories and inhalation technologies. The value of 0.00 serves as a current metric that allows for the comparison of the company's market value with its earnings growth rate.

ALT - Altimmune PEG Multiple over the range 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for Altimmune, Inc. (ALT)

- market price and analyst price targets:

Stock Quotes Altimmune Inc|ALT - Analyst Consensus Forecast

- market capitalization information:

Market Value Altimmune Corp|ALT - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Book Price of a Share Altimmune|ALT - Book Capitalization|Market Capitalization to Book Value Ratio altimmune.com|ALT - Company Total Assets

- business debt structure and liquidity details:

- earnings and market ratios statistics:

ALT - Company Net Income|Future Profit Altimmune, Inc.|ALT - P/E Multiple|Forward P/E Multiple Altimmune Pharma|ALT - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp|ALT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Altimmune|ALT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months altimmune.com|ALT - Earnings per share growth in current year|Expected earnings per share growth for next year Altimmune, Inc.

Fundamental company analysis:Altimmune Inc ALT

This metric correlates market capitalization with earnings growth rates, allowing for the identification of an undervalued asset when the value falls below one. By analyzing the average peg_co level, an investor assesses the growth potential of Altimmune, Inc. (ALT) as its anti-obesity drug prepares for large-scale testing and the company seeks a strategic pharmaceutical partner to execute late-stage research.

Competing companies